← Back to patent-cliff list
MT-501
Tier C — Watch / tradeMT-501
Mirador Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Crohn's disease, Ulcerative colitis, Inflammatory bowel disease
Regional status
US
Phase II
2025-06-26
EU
Phase II
2025-06-26
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of MT-501?
Approved indications include: Crohn's disease, Ulcerative colitis, Inflammatory bowel disease.
When does the MT-501 patent expire?
No public expiry year is available for MT-501 yet; this page updates once verified.
How do I get a quote for MT-501 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30